- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
- Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
- Axsome Therapeutics to Present at Upcoming Investor Conferences
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
More ▼
Key statistics
As of last trade Axsome Therapeutics Inc (0HKF:LSE) traded at 81.03, -17.46% below its 52-week high of 98.17, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 81.03 |
Average volume | 393.78 |
---|---|
Shares outstanding | 47.50m |
Free float | 38.30m |
P/E (TTM) | -- |
Market cap | 3.75bn USD |
EPS (TTM) | -6.38 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 15:36 BST.
More ▼